KPV
KPV
Also known as: KPV Tripeptide, Alpha-MSH Fragment 11-13
Overview
Key Facts
Primary Goal: A tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH)
A tripeptide derived from the C-terminal end of alpha-melanocyte stimulating hormone (α-MSH). Possesses potent anti-inflammatory properties without the melanogenic effects of the parent hormone. Half-Life ~30 minutes Typical Dose 200–500 mcg Frequency 1-2x daily Cycle Length 4-12 weeks
Dosing Information
Half-Life
~30 minutes
Typical Dose
200–500 mcg
Frequency
1-2x daily
Cycle Length
4-12 weeks
Administration Routes:
Storage & Reconstitution
Unreconstituted (Powder)
Reconstituted (Mixed)
Research Summary
Studied primarily in preclinical models of colitis, skin inflammation, and infection. Demonstrated ability to reduce intestinal inflammation in IBD mouse models comparable to standard treatments. Strong in vitro evidence for NF-kB pathway inhibition.
Frequently Asked Questions
Common questions about KPV
UK-Specific Information
Exclusive data points and guidance for UK residents using KPV
UK Lab Testing
US Lab Testing
Recommended labs: Quest Diagnostics, LabCorp ($120-$200 for peptide safety panel)
Why this matters: UK-specific lab testing guidance not available on US competitor sites
Commonly Stacked With
5-Amino-1MQ
Research and therapeutic applications of 5-Amino-1MQ
Ac-SDKP
Research and therapeutic applications of Ac-SDKP
ACE-031
Research and therapeutic applications of ACE-031
Acetyl Hexapeptide-3
Research and therapeutic applications of Acetyl Hexapeptide-3
AHK-Cu
Research and therapeutic applications of AHK-Cu
Alcohol Prep Pads
Research and therapeutic applications of Alcohol Prep Pads
Note: Peptide stacking should only be done under the guidance of a qualified healthcare professional. Individual responses may vary.